pcDNA3.2 TDP-43 YFP Citations (4)

Originally described in: Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rub U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD Nature. 2010 Aug 26;466(7310):1069-75. doi: 10.1038/nature09320. PubMed Journal

---

Articles Citing pcDNA3.2 TDP-43 YFP

Articles
Establishment of chemically oligomerizable TAR DNA-binding protein-43 which mimics amyotrophic lateral sclerosis pathology in mammalian cells. Yamanaka Y, Miyagi T, Harada Y, Kuroda M, Kanekura K. Lab Invest. 2021 Oct;101(10):1331-1340. doi: 10.1038/s41374-021-00623-4. Epub 2021 Jun 15. PubMed
Nuclear RNA binding regulates TDP-43 nuclear localization and passive nuclear export. Duan L, Zaepfel BL, Aksenova V, Dasso M, Rothstein JD, Kalab P, Hayes LR. Cell Rep. 2022 Jul 19;40(3):111106. doi: 10.1016/j.celrep.2022.111106. PubMed
Astrocytic TDP-43 dysregulation impairs memory by modulating antiviral pathways and interferon-inducible chemokines. Licht-Murava A, Meadows SM, Palaguachi F, Song SC, Jackvony S, Bram Y, Zhou C, Schwartz RE, Froemke RC, Orr AL, Orr AG. Sci Adv. 2023 Apr 21;9(16):eade1282. doi: 10.1126/sciadv.ade1282. Epub 2023 Apr 19. PubMed
RNA-binding properties orchestrate TDP-43 homeostasis through condensate formation in vivo. Scherer NM, Maurel C, Graus MS, McAlary L, Richter G, Radford RAW, Hogan A, Don EK, Lee A, Yerbury J, Francois M, Chung RS, Morsch M. Nucleic Acids Res. 2024 May 22;52(9):5301-5319. doi: 10.1093/nar/gkae112. PubMed

If you have published an article using this material, please email us at to have your article added to this page.